Gene Therapy Slowed Huntington Disease Progression
Researchers reported that a new gene therapy reduced disease progression by 75 percent in a clinical trial.
Updated on Oct. 13, 2026 in Stroke
Live Poll
Should medical breakthroughs be considered valid before completing large-scale, placebo-controlled clinical trials?
In 2025, scientists published findings showing that a gene therapy named AMT-130 significantly slowed the progression of Huntington disease. The treatment aims to target the genetic root of the condition by reducing the production of toxic proteins.
Why it matters
Huntington disease is caused by a mutation in the HTT gene, which leads to progressive brain damage. By introducing new material into brain cells, this therapy attempts to address the underlying cause of the condition rather than just managing symptoms.
A Phase 1/2 trial involving 29 patients over 36 months showed a 75 percent reduction in disease progression among treated participants. Additionally, brain damage markers, specifically light protein, decreased by an average of 8.2 percent from baseline.
The players
UniQure
This biotechnology company is the developer of the AMT-130 gene therapy and is managing the clinical trials.
University College London
This public research university collaborated on the clinical trial to evaluate the efficacy of the new gene therapy.
The details
The experimental therapy AMT-130 is administered via a procedure directly into the striatum to introduce working material into cells. This mechanism works by lowering the presence of toxic huntingtin protein production, which is responsible for the disease progression.
Timeline
Clinical trial results were published in 2025.
The developer plans to seek regulatory approval in early 2026.
Health Landscape
This development marks a significant shift in neurodegenerative care by moving toward gene-targeted interventions. Having earned the FDA's breakthrough therapy designation, the treatment follows a pattern set by other advanced medical innovations intended to accelerate the path to regulatory approval.
While the therapy is not currently available to the public, successful regulatory approval could eventually expand treatment options for patients living with the genetic condition. Patients and families should discuss the status of emerging clinical trials with their healthcare providers to understand potential eligibility.
The takeaway
This study highlights the growing potential for gene therapy to intervene in inherited neurological disorders at their molecular source. Patients should continue to monitor updates from clinical trial sponsors for information regarding future availability and broader access.
What happens next
UniQure is expected to initiate the formal process for FDA regulatory approval for AMT-130 in early 2026.
Further reading
Learn more about the latest research on Stroke treatments and therapeutic innovations.
Source note: This article includes information reported by The Times of India.
Live Poll
Should medical breakthroughs be considered valid before completing large-scale, placebo-controlled clinical trials?
